uniQure Announces 2016 Financial Results And Provides Update On Company Progress
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 15, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with severe medical needs, today announces its financial results for the year 2016 and provides an update on company progress.
“In 2016, we made significant progress across all of our core programs and implemented strategic changes that have strengthened our organization and enhanced focus on our key priorities,” stated Matthew Kapusta, chief executive officer of uniQure. “We enter 2017 with a solid financial position and strong clinical data to advance our hemophilia B program into a Phase III study, as well as to progress our gene therapy candidates in Huntington’s disease and congestive heart failure towards IND filings. We believe the achievement of these objectives will deliver meaningful value to shareholders.”
“In 2016, we made significant progress across all of our core programs and implemented strategic changes that have strengthened our organization and enhanced focus on our key priorities,” stated Matthew Kapusta, chief executive officer of uniQure. “We enter 2017 with a solid financial position and strong clinical data to advance our hemophilia B program into a Phase III study, as well as to progress our gene therapy candidates in Huntington’s disease and congestive heart failure towards IND filings. We believe the achievement of these objectives will deliver meaningful value to shareholders.”